3.8201

2.54% 0.0801

Fulcrum Therapeutics Inc (FULC)

Overview News Price History Option Chain Financials Discussions Forecast

Fulcrum Therapeutics Inc stock is traded at $3.8201, with a volume of 6.48M. It is up +2.54% in the last 24 hours and up +5.07% over the past month. Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Previous Close:

$3.74

Open:

$3.81

24h Volume:

6.48M

Relative Volume:

2.51

Market Cap:

$292.22M

Revenue:

$80.00M

Net Income/Loss:

$-76.12M

P/E Ratio:

-3.332

EPS:

-1.1465

Net Cash Flow:

$-63.88M

1W Performance:

+2.27%

1M Performance:

+5.07%

6M Performance:

-64.02%

1Y Performance:

-43.77%

1-Day Range:

$3.7514

$3.90

1-Week Range:

$3.615

$3.90

52-Week Range:

$2.83

$15.74

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name

Fulcrum Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

617-651-8851

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

Twitter

@fulcrumtx

Next Earnings Date

2026-08-04

Latest SEC Filings

FULC's Discussions on Twitter

Compare FULC vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FULC Fulcrum Therapeutics Inc	3.83	285.35M	80.00M	-76.12M	-63.88M	-1.1465
VRTX Vertex Pharmaceuticals Inc	515.44	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.90	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.82	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.68	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.27	39.31B	5.76B	514.49M	1.10B	4.4813

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-12-26	Initiated	JP Morgan	Overweight
Nov-24-25	Initiated	Truist	Buy
Jul-29-25	Upgrade	H.C. Wainwright	Neutral → Buy
May-23-25	Upgrade	Leerink Partners	Market Perform → Outperform
May-15-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Sep-13-24	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-12-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-12-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-12-24	Downgrade	Stifel	Buy → Hold
Sep-09-24	Upgrade	BofA Securities	Underperform → Neutral
May-20-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-24	Initiated	RBC Capital Mkts	Outperform
Sep-25-23	Initiated	Goldman	Neutral
Aug-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Aug-22-23	Upgrade	Stifel	Hold → Buy
May-04-23	Downgrade	Goldman	Buy → Neutral
Mar-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Mar-10-23	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-09-23	Downgrade	Stifel	Buy → Hold
Feb-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-24-23	Downgrade	BofA Securities	Neutral → Underperform
Nov-15-22	Initiated	Goldman	Buy
Mar-08-22	Initiated	Oppenheimer	Outperform
Mar-03-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-11-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-22-21	Initiated	Credit Suisse	Outperform
Mar-02-21	Initiated	Stifel	Buy
Oct-16-20	Initiated	Piper Sandler	Overweight
Aug-12-20	Downgrade	BofA Securities	Neutral → Underperform
Aug-12-20	Reiterated	H.C. Wainwright	Buy
Aug-12-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-19-20	Downgrade	BofA/Merrill	Buy → Neutral
Jun-17-20	Initiated	BTIG Research	Buy
Oct-03-19	Initiated	H.C. Wainwright	Buy
Aug-12-19	Initiated	BofA/Merrill	Buy

View All

Fulcrum Therapeutics Inc Stock (FULC) Latest News

02:28 AM

Fulcrum Therapeutics to Merge With Slate Medicines in $245 Million Backed Migraine Play - finance.biggo.com

02:28 AM

01:41 AM

Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire

01:41 AM

01:16 AM

Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines - benzinga.com

01:16 AM

12:11 PM

Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies - Yahoo Finance

12:11 PM

11:53 AM

Fulcrum Therapeutics shutting down reverse merger with Slate Medicines - The Business Journals

11:53 AM

11:14 AM

Fulcrum Therapeutics Target of Unusually Large Options Trading (NASDAQ:FULC) - MarketBeat

11:14 AM

10:48 AM

Fulcrum Therapeutics and Slate Medicines to merge, refocusing combined company on migraine pipeline - The Pharma Letter

10:48 AM

10:13 AM

Fulcrum Therapeutics stock rises on Slate Medicines merger deal - Investing.com

10:13 AM

09:23 AM

Fulcrum to merge with Slate in all-stock deal after drug setback - Reuters

09:23 AM

09:07 AM

Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal - MarketBeat

09:07 AM

08:50 AM

Transcript : Fulcrum Therapeutics, Inc., Slate Medicines, Inc.M&A Call - marketscreener.com

08:50 AM

08:36 AM

Form 8K Fulcrum Therapeutics Inc For: 17 August By Investing.com - Investing.com UK

08:36 AM

08:34 AM

Fulcrum (NASDAQ: FULC) investors get cash but small stake post‑Slate deal - Stock Titan

08:34 AM

08:33 AM

Fulcrum Therapeutics to Merge With Slate Medicines in Stock Deal Backed by $245 Million Financing - TradingView

08:33 AM

07:52 AM

Why is Fulcrum Therapeutics stock rallying today? - Investing.com

07:52 AM

07:23 AM

Fulcrum Therapeutics to merge with Slate Medicines in $245M deal - Investing.com Australia

07:23 AM

07:15 AM

Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies - The Manila Times

07:15 AM

Aug 14, 2026

Therapeutics, Inc. (FULC) RA Capital group now reports 0.0% stake - Stock Titan

Aug 14, 2026

Therapeutics, Inc. (FULC) 8.22% stake disclosed by Nantahala Capital - Stock Titan

Aug 14, 2026

Fulcrum Therapeutics (FULC): Montanova and affiliates report 5.5% ownership stake - Stock Titan

Aug 14, 2026

Fulcrum Therapeutics (FULC) investor group reduces reported ownership to 0% - Stock Titan

Aug 14, 2026

Kaplan Fox Investigates Fulcrum Therapeutics After 51% Stock Plunge Following Pociredir Program Halt - Kalkine Media

Aug 14, 2026

Assenagon Asset Management S.A. Has $3.06 Million Position in Fulcrum Therapeutics, Inc. $FULC - MarketBeat

Aug 14, 2026

Aug 13, 2026

Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDA - The National Law Review

Aug 13, 2026

Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations - FinancialContent

Aug 13, 2026

Aug 12, 2026

Kaplan Fox Launches Securities Probe into Fulcrum Therapeutics Following 51% Stock Plunge After Pociredir Program Halt - Kalkine Media

Aug 12, 2026

Fulcrum Therapeutics Faces Securities Law Investigation After Pociredir Program Discontinuation Triggers 51% Stock Drop - kalkine.ca

Aug 12, 2026

Aug 11, 2026

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review

Aug 11, 2026

Aug 10, 2026

Fulcrum Therapeutics stock plunges 51% after FD... - Pluang

Aug 10, 2026

Fulcrum Therapeutics Appoints Alan Musso as Principal Accounting Officer Amid Leadership Change - Kalkine Media

Aug 10, 2026

Form 8K Fulcrum Therapeutics Inc For: 10 August By Investing.com - Investing.com Australia

Aug 10, 2026

Fulcrum Therapeutics appoints Alan Musso as principal accounting officer By Investing.com - Investing.com Nigeria

Aug 10, 2026

Fulcrum Therapeutics appoints Alan Musso as principal accounting officer - Investing.com

Aug 10, 2026

Fulcrum Therapeutics, Inc. Appoints Alan Musso as Principal Accounting Officer, Effective August 7, 2026 - marketscreener.com

Aug 10, 2026